Board Member
Abeona Therapeutics Inc. (ABEO)Equibles does not estimate personal net worth.
Get an email with a short summary when Abeona Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get ABEO alertsVishwas Seshadri is recorded as Board Member and CEO at Abeona Therapeutics Inc. (ABEO). The newest filing on record that lists Vishwas Seshadri as Board Member and CEO at Abeona Therapeutics Inc. (ABEO) is dated April 27, 2026. Abeona Therapeutics Inc. reported in an 8-K filed April 24, 2024 that Vishwas Seshadri was appointed Class 2 director, effective April 24, 2024. Vishwas Seshadri has spoken on 13 earnings calls and 2 other investor events across 1 company, most recently for Abeona Therapeutics Inc. on September 16, 2026. Abeona Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Abeona Therapeutics Inc. includes Michael Amoroso (CEO, Chairman, COO and Board Member), Brian J.G. Pereira (Chairman and Board Member), Edward Carr (CFO) and 7 others.
“Leila Alland and Vishwas Seshadri were elected to serve as Class 2 directors of the Company until the 2027 annual meeting of stockholders and until their successors are elected and qualified.”
“I'm the president and CEO of Aviona, and it's a pleasure to attend the Morgan Stanley Conference, and this is a very important year for us, the first full year of launch since we got our first approval, so very excited to be here.”
“Abiona is a cell and gene therapy company. Our focus is autologous ex vivo engineered cell therapy, and our lead product is Zivaskin. This was approved by the FDA for treating patients with wounds and patients with recessive dystrophic EB, and that approval happened in April 2025.”
“First, we are excited to share updates on leading indicators of ZivaSkin adoption that signal strong momentum since treating our first commercial patient in December.”
“We continue to see growing patient demand for ZivaSkin, the first and only autologous cell-based gene therapy for the treatment of adults and pediatric patients with recessive dystrophic epidemiolysis bullosa, or RDV.”
“The 2025 was marked by significant operational progress as we continue to scale the ZivaSkin commercial launch to meet growing patient demand.”
Start not stated–present
Last confirmed April 27, 2026
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
Board Member, CEO
